GLP-1 Market
LLY $1150.99 ▼ -1.6% NVO $38.17 ▼ -3.1% PFE $28.18 ▲ +0.9% VKTX $41.65 ▲ +2.0% KLRA $13.13 ▲ +2.7% GPCR $35.95 ▼ -2.6% RHHBY $55.06 ▼ -0.9%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

JNJ-79635322

JNJ-79635322

Company
Janssen Research & Development, LLC
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
7 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

7 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 24, 2026

Find a Clinical Trial Near Me

See recruiting studies for JNJ-79635322 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT05652335

    A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

    Not yet reported Janssen Research & Development, LLC 180 participants Est. completion 2030-11-15 29 sites Stand-alone
    Other conditions: Relapsed or Refractory Multiple Myeloma, Previously Treated Amyloid Light-chain (AL) Amyloidosis
    View official trial listing →
  • Recruiting NCT NCT05695508

    GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5

    Not yet reported University of Heidelberg Medical Center 160 participants Est. completion 2029-09-15 11 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT06768489

    A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 240 participants Est. completion 2029-06-29 16 sites Stand-alone
    Other conditions: Multiple Myeloma, Smoldering Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis
    View official trial listing →
  • Recruiting NCT NCT07258511

    A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 400 participants Est. completion 2031-09-30 144 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT07266441

    A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 157 participants Est. completion 2028-12-12 71 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT07518186

    A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 700 participants Est. completion 2032-12-08 151 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT07589634

    A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 230 participants Est. completion 2030-11-08 9 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.